Skip to main content
For Healthcare
Professionals
Therapeutic areas
Products
Tools
Contact
Norwegian Nynorsk
Therapeutic areas
Hematology
Products
Aspaveli
Kineret
Doptelet
Elocta
Tools
Contact
Heim
Products
Elocta
About haemophilia A
About haemophilia A
The impact of haemophilia
Is FVIII still fundamental?
Personalised protection
Indications for ELOCTA
Mechanism of action
Personalised prophylaxis
Efficacy
Robust trial programme
Bleed protection
Safety profile
Safety profile
Additional information
Administration
Resources
Prescribing information
About Haemophilia A
The impact of haemophilia
Read more
Is FVIII still fundamental?
Read more
Personalised protection
Read more
FVIII, factor VIII.
PP-20365
Oct, 2023
Therapeutic areas
Hematology
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Products
Aspaveli
About PNH
Patient Burden
Ongoing anaemia
Mechanism of action
Efficacy
Clinical Efficacy
Patient outcomes
Safety
Safety Profile
Before Prescribing
Administration
Self-administration
Starting Aspaveli
Resources
Kineret
This is how Kineret works
Resources
Prescribing information
Doptelet
Introduction to ITP
About ITP
Challenge expectations in ITP
Today’s expectations
Challenge expectations
Efficacy
Durable response within 8 days
Consistent response
Effect and durable response
Dosing
Safety profile
Guidelines
Resource centre
Prescribing information
Elocta
About haemophilia A
The impact of haemophilia
Is FVIII still fundamental?
Personalised protection
Indications for ELOCTA
Mechanism of action
Personalised prophylaxis
Efficacy
Robust trial programme
Bleed protection
Safety profile
Safety profile
Additional information
Administration
Resources
Prescribing information
Tools
Contact
Login
Other sites
expand_less
